David Klinzing, PhD, is a molecular and computational biologist with many years of experience in research, academia, and biotechnology, particularly in DNA sequencing and NGS. David was involved in one of the first genome projects—the E. coli genome project at the University of Wisconsin—as an undergraduate and has done extensive DNA sequencing, genomics, and computational work over his career. After receiving his PhD from Tufts University in the US, David completed a post-doctoral stint at Harvard Medical School exploring the regulation of gene expression in Group B Streptococcus, a leading cause of neonatal meningitis, in response to the innate immune system, utilizing computational genomic approaches and in vivo animal models.
In 2009, David moved to the Philippines and helped introduce next-generation sequencing to the country while teaching NGS and genomics at the university and graduate school levels. David moved with his family to Singapore in 2013 and joined AITbiotech to run their laboratory and NGS services, which eventually became NovogeneAIT, a joint venture with Novogene, China, where David established their human whole genome sequencing laboratory, including building their biocomputing capabilities, and focused on NGS projects such as the SG10K, Singapore’s 10,000 genomes project. David co-founded Compass Genetics in Singapore in 2017 to help bring clinical genomics to the region, and in 2020, he became CTO and General Manager of Asia Genomics and Imagene Labs to oversee the consumer genetics and personalized products division. David co-founded Next Level Genomics in 2022.